Number needed to treat and cost per remitter for biologic treatments of Crohn’s disease in Japan

References

• Loftus EV Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60.
   PubMed Web of Science ®Google Scholar
• Asakura K, Nishiwaki Y, Inoue N, et al. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44:659–665.
   PubMed Web of Science ®Google Scholar
• Antunes O, Filippi J, Hebuterne X, et al. Treatment algorithms in Crohn’s – up, down or something else? Best Pract Res Clin Gastroenterol. 2014;28:473–483.
   PubMed Web of Science ®Google Scholar
• Bodger K. Cost of illness of Crohn’s disease. Pharmacoeconomics. 2002;20:639–652.
   PubMed Web of Science ®Google Scholar
• Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319–328.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol. 2000;95:524–530.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91–96.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Betts KA, Signorovitch JE, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr Med Res Opin. 2018;34:1325–1333.
   PubMed Web of Science ®Google Scholar
• Betts KA, Griffith J, Song Y, et al. Network meta-analysis and cost per responder of tumor necrosis factor-α and interleukin inhibitors in the treatment of active ankylosing spondylitis. Rheumatol Ther. 2016;3:323–336.
   PubMed Web of Science ®Google Scholar
• Gissel C, Repp H. Cost per responder of TNF-α therapies in Germany. Clin Rheumatol. 2013;32:1805–1809.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Fanizza C, Gilio M, et al. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis. Clin Exp Rheumatol. 2016;34:935–940.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012;29:620–634.
   PubMed Web of Science ®Google Scholar
• NIH U.S. National Library of Medicine. ClinicalTrials.gov.
   Google Scholar
• University hospital Medical Information Network. UMIN Clinical Trials Registry (UMIN-CTR). [cited Jan 29]. Available from: https://www.umin.ac.jp/ctr/
   Google Scholar
• Japan Pharmaceutical Information Center. Clinical trial information (Japic Clinical Trials Information). [cited 2019 Jan 29]. Available from: https://www.clinicaltrials.jp/cti-user/common/Top.jsp.
   Google Scholar
• The Japan Medical Association Center for Clinical Trials. JMACCT Clinical Trials Registry. [cited 2019 Jan 29]. Available from: https://dbcentre3.jmacct.med.or.jp/jmactr/Default_Eng.aspx.
   Google Scholar
• NPO Japan Medical Abstracts Society. ICHUSHI. [cited 2019 Jan 29]. Available from: https://www.jamas.or.jp/english/.
   Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349–1362.
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148:344–354 e345. quiz e314-345.
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291–1302.
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018;48:394–409.
   PubMed Web of Science ®Google Scholar
• Vermeire S, van Assche G, Rutgeerts P. Review. article: Altering the natural history of Crohn’s disease–evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3–12.
   PubMed Web of Science ®Google Scholar
• Japan Ministry of Health Labour and Welfare. The Medical Fee Schedule 2018. https://www.mhlw.go.jp/index.html
   Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6:160–173.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Nakano A, Dakeshita H, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. J Dermatolog Treat. 2018;29:24–31.
   PubMed Web of Science ®Google Scholar
• IBM Watson Health. Micromedex RED BOOK – a comprehensive, consistent drug pricing resource. [2018 Sep]. Available from: http://truvenhealth.com/Products/Micromedex/Product-Suites/Clinical-Knowledge/RED-BOOK.
   Google Scholar
• MIMS. The monthly index of medical specialities. [2018 Sep]. Available from: https://www.mims.co.uk/.
   Google Scholar
• Rote Liste. Rote Liste Service GmbH. [2018 Sep]. Available from: https://www.rote-liste.de/.
   Google Scholar
• Kanatani Y, Tomita N, Sato Y, et al. National registry of designated intractable diseases in Japan: present status and future prospects. Neurol Med Chir (Tokyo). 2017;57:1–7.
   PubMed Web of Science ®Google Scholar
• The Central Social Insurance Medical Council. Draft outline of drug pricing system reform. [2018 May]. Available from: http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000188706.pdf.
   Google Scholar
• Saito S, Nakazawa K, Suzuki K, et al. Paradigm shift of healthcare cost for patients with inflammatory bowel diseases: a claims data-based analysis in Japan. Gastrointestin Disord. 2019;1:120–128.
   Google Scholar
• Kasper LH, Everitt D, Leist TP, et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin. 2006;22:1671–1678.
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D’Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther. 2001;15:463–473.
   PubMed Web of Science ®Google Scholar
• den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2288–2298.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–1141.
   PubMed Web of Science ®Google Scholar
• Organization for Economic Co-operation and Development (OECD). Purchasing Power Parities. [2018 May]. Available from: https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm.
   Google Scholar